Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828980 | 0.90 | TRPV1 (0.57) | TRPV1IDO1 | |
| SCHEMBL16363169 | 0.84 | HPGD (0.52) | KDM4ENPC1RAB9A | |
| SCHEMBL16363171 | 0.83 | LMNA (0.61) | KDM4ENPC1RAB9A | |
| SCHEMBL16363172 | 0.82 | KCNK3 (0.47) | TRPV1NPC1RAB9AS1PR1S1PR3 | |
| SCHEMBL16363156 | 0.81 | IDO1 (0.47) | TRPV1IDO1 | |
| SCHEMBL16363163 | 0.81 | S1PR1 (0.59) | NPC1RAB9AS1PR1 | |
| SCHEMBL16363175 | 0.81 | KCNK3 (0.47) | TRPV1IDO1S1PR1S1PR3 | |
| SCHEMBL16363178 | 0.81 | NR2E1 (0.56) | TRPV1KDM4ES1PR1S1PR3 | |
| SCHEMBL16363170 | 0.80 | TRPV1 (0.44) | TRPV1IDO1NPC1RAB9A | |
| SCHEMBL16363174 | 0.80 | PTGES (0.46) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | TRPV1 795/4885IDO1 249/4885KDM4E 2452/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | TRPV1 795/4885IDO1 249/4885KDM4E 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.